Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,318.00
Bid: 1,315.00
Ask: 1,319.00
Change: 43.00 (3.37%)
Spread: 4.00 (0.304%)
Open: 1,289.00
High: 1,318.00
Low: 1,267.00
Prev. Close: 1,275.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Indivior shares down on swing to annual loss

Thu, 16th Feb 2023 10:09

(Alliance News) - Indivior PLC on Thursday reported a swing to a full-year loss due to a provision for litigation, despite net revenue jumping by 14% due to growth in its Sublocade injection.

Shares were down 12% at 1,719 pence each on Thursday morning in London.

The Richmond, Virginia-based pharmaceutical firm swung to a pretax loss of USD95 million in 2022 from a profit of USD190 million in 2021, despite a jump by 14% in net revenue to USD901 million from USD791 million.

Indivior booked a USD290 million exceptional provision in 2021, as it navigates initial mediation sessions in late January regarding legacy civil multi-district antitrust litigation.

"Because these matters are in various stages, Indivior cannot predict with any certainty how these matters will ultimately be resolved, or the costs, or timing of such resolution. In particular, any final aggregate costs of these matters, whether resolved by settlement or trial, may be materially different from this provision," the company said.

Operating loss was USD85 million in 2022, compared to a profit of USD213 million the year before. However, on an adjusted basis, operating profit rose by 13% to USD212 million from USD187 million.

In the fourth quarter alone, net revenue amounted to USD241 million, up from USD222 million a year earlier. Indivior swung to a pretax loss of USD256 million in the quarter, from a profit of USD39 million a year before, though adjusted operating profit rose by 25% to USD40 million form USD32 million.

The company said the net revenue growth was primarily driven by Sublocade.

Chief Executive Officer Mark Crossley said: "I am pleased to report another strong year of execution against our strategic priorities, resulting in double-digit underlying growth across our key financial metrics."

Looking ahead, Indivior expects net revenue for 2023 to be in the range of USD950 million to USD1.02 billion, reflecting strong growth in Perseris and Sublocade.

Perseris is an extended-release injection for schizophrenia, while Sublocade is buprenorphine extended-release injection for opioid addiction, both of which are long-acting injectable products

By Xindi Wei, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
21 Aug 2023 07:23

Indivior settles part of US suboxone litigation

(Sharecast News) - Addiction treatment specialist Indivior announced on Monday that its US subsidiary has entered into an agreement to settle the claims initiated by the end payor class in the ongoing multi-district suboxone antitrust litigation.

Read more
1 Aug 2023 17:39

TRADING UPDATES: C4X Discovery inks Indivior deal, Digitalbox expands

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Jul 2023 09:46

LONDON BROKER RATINGS: KBW cuts Aviva 'market perform'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
27 Jul 2023 11:48

Indivior raises 2023 guidance after strong half-year progress

(Alliance News) - Indivior PLC on Thursday celebrated a strong recent six months and second quarter that brough increased profit and revenue, boosting its optimism for the rest of the year.

Read more
27 Jul 2023 10:04

Indivior lifts guidance after strong first half

(Sharecast News) - Pharmaceuticals firm Indivior reported a 24% improvement in net revenue in its half-year report on Thursday, to $529m.

Read more
12 Jun 2023 07:53

LONDON BRIEFING: Shares on the rise; Frasers buys into AO World

(Alliance News) - Stocks in London were set to open higher on Monday, at the start of a busy week of central bank moves.

Read more
5 Jun 2023 07:46

Indivior reaches settlement in litigation with US states

(Sharecast News) - Addiction treatment-focussed pharmaceuticals company Indivior announced on Monday that its subsidiary Indivior Inc has successfully reached an agreement to resolve the claims brought against it by the attorneys general of 41 US states and the District of Columbia.

Read more
2 Jun 2023 18:18

Indivior settles antitrust claims in US regarding Suboxone drug

(Alliance News) - Indivior PLC on Friday said it has reached an agreement to resolve the claims brought in antitrust multi-district litigation regarding its drug Suboxone.

Read more
25 May 2023 09:23

LONDON BROKER RATINGS: Numis starts Tristel with 'add'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
23 May 2023 09:56

Indivior emergency opioid overdose treatment approved by US FDA

(Alliance News) - Indivior PLC on Tuesday said the US Food & Drug Administration has approved its OPVEE nasal spray for the emergency treatment of opioid overdose.

Read more
23 May 2023 07:48

Indivior's opioid addiction sprat approved by FDA

(Sharecast News) - US health regulators have approved Indivior's Opvee nasal spray treatment for opiod addiction, the company said on Tuesday.

Read more
10 May 2023 17:02

DIRECTOR DEALINGS: Indivior division chief sells GBP1.7 million shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Wednesday and not separately reported by Alliance News:

Read more
27 Apr 2023 15:49

UK shareholder meetings calendar - next 7 days

Friday 28 April 
AQRU PLCAGM
Audioboom Group PLCAGM
BBGI Global Infrastructure SAAGM
Everest Global PLCAGM
GetBusy PLCAGM
Greencoat Renewables PLCAGM
Greencoat UK Wind PLCAGM
Hikma Pharmaceuticals PLCAGM
JPMorgan Claverhouse Investment Trust PLCAGM
Kingspan Group PLCAGM
ME Group International PLCAGM
Minoan Group PLCAGM
Pearson PLCAGM
Rotork PLCAGM
Shanta Gold LtdAGM
Smurfit Kappa Group PLCAGM
Symphony International Holdings LtdAGM
Monday 1 May 
no events scheduled 
Tuesday 2 May 
Carr's Group PLCGM re annual report and directors remuneration report
CVC Income & Growth LtdAGM
IOG PLCAGM
Ocado Group PLCAGM
Plus500 LtdAGM
Wednesday 3 May 
Apax Global Alpha LtdAGM
Barclays PLCAGM
GSK PLCAGM
Hyve Group PLCCourt Meeting & GM re acquisition by Heron UK Bidco Ltd
Logistics Development Group PLCAGM
Okyo Pharma LtdGM re proposed cancellation of the ordinary shares of no par value
Reach PLCAGM
Reckitt Benckiser Group PLCAGM
Standard Chartered PLCAGM
Tritax Big Box REIT PLCAGM
Unilever PLCAGM
Thursday 4 May 
AIB Group PLCAGM
Aviva PLCAGM
Aviva PLCGM re capital reduction
BAE Systems PLCAGM
Bivictrix Therapeutics PLCAGM
Domino's Pizza Group PLCAGM
Glanbia PLCAGM
Grafton Group PLCAGM
Hammerson PLCAGM
Howden Joinery Group PLCAGM
Hurricane Energy PLCCourt Meeting & GM re takeover by Prax Exploration & Production PLC  
Indivior PLCAGM
IMI PLCAGM
Irish Residential Properties REIT PLCAGM
ITV PLCAGM
Jardine Matheson Holdings LtdAGM
Johnson Service Group PLCAGM
LungLife AI IncAGM
Mincon Group PLCAGM
Mondi PLCAGM
Moneysupermarket.com Group PLCAGM
Morgan Sindall Group PLCAGM
Spirent Communications PLCAGM
Personal Group Holdings PLCAGM
Phoenix Group Holdings PLCAGM
Rathbones Group PLCAGM
SIG PLCAGM
Ten Entertainment Group PLCAGM
Travis Perkins PLCAGM
Witan Investment Trust PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
27 Apr 2023 14:41

Indivior lifts revenue guidance, cuts profit outlook after Opiant deal

(Sharecast News) - Opioid addiction treatment maker Indivior lifted its full-year revenue guidance on Thursday but trimmed its outlook for operating profit due to costs related to the acquisition of Opiant Pharmaceuticals, as it posted a jump in first-quarter profit and revenue.

Read more
27 Apr 2023 13:46

Indivior raises 2023 revenue forecast following Opiant acquisition

(Alliance News) - Indivior PLC on Thursday said net revenue increased by more than 20% in the first quarter, lifting profit, and it updated its guidance for the year following its acquisition of Opiant Pharmaceuticals Inc last month.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.